with improved clinical profiles entering the market and the continued uptake of products with a high
ACOT. The market is then expected to plateau until 2024 as generic erosion of key brands,
including Tecfidera, Aubagio, and Gilenya, offsets potential growth driven by pipeline drug uptake.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the
purchase.
Request a Sample Copy of This Report @
http://www.radiantinsights.com/research/multiple-sclerosis-canada-drug-forecast-and-
market-analysis-to-2024/request-sample
Scope
- Overview of MS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Canada including product MScription, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Canada from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Canada MS
market.
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Canada.
See More Reports of This Category by Radiant Insights @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Follow Us: